NCT06451458

ECHO for Diabetes and Multiple Chronic Conditions Study

Enrolling by Invitation
NAAges 18–89InterventionalTreatment
University of New Mexico
~20 participants
Updated 2026-07-30 on ClinicalTrials.gov
What's tested:ECHO program for DMMCUsual care

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
HbA1c trajectory
Measured over At least once every 6 months per Electric Health Record (EHR), during 12 months baseline prior to intervention, during 18 months intervention.
+1 more outcome measured
Diabetes Mellitus
Chronic Disease
1 sites across 1 states
New Mexico1
  • Yiliang Zhu, PhD · PRINCIPAL_INVESTIGATOR · University of New Mexico Health Science Center
  • Matthew Bouchonville, MD · PRINCIPAL_INVESTIGATOR · University of New Mexico Health Science Center
  • Vallabh Shah, PhD · STUDY_DIRECTOR · University of New Mexico Health Science Center

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Twenty PMS sites with the highest patient volume.
All members of the PMS sites (participants) healthcare teams between 18 and 89 years of age, all genders, and all ethnicities.
  • HbA1c trajectoryAt least once every 6 months per Electric Health Record (EHR), during 12 months baseline prior to intervention, during 18 months intervention.

    A decreasing trajectory in patients' HbA1c over time during and following ECHO intervention, reaching an average of 0.5% drop 18 months into intervention compared with comparator

  • HbA1c level in controlAt least once every 6 months per Electric Health Record (EHR), during 12 months baseline prior to intervention, during 18 months intervention.

    15% decreases in per-patient rate of HbA1c\>8.5% by 18 months into intervention, respectively, compared with comparator